Volume 4 Number 10 December 2003/January 2004 PDF
1 December 2003. Related: PDFs.
2003
Volume 4 Number 10 December 2003
1 December 2003. Related: Editorial.
9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw
1 December 2003. Related: Conference reports.
Lower doses of d4T produce similar efficacy and reduced side effects
1 December 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching from efavirenz to nevirapine to avoid CNS side effects
1 December 2003. Related: Conference reports, Antiretrovirals, Side effects.
Interruption of treatment is safe for those who started too early
1 December 2003. Related: Conference reports, Treatment strategies.
T20 is cost effective for UK purchasers
1 December 2003. Related: Conference reports, Antiretrovirals.
Intrauterine exposure to efavirenz
1 December 2003. Related: Conference reports, Women's health, Pregnancy, Side effects.
African patients and adherence in the UK
1 December 2003. Related: Conference reports, Antiretrovirals.
Five-year results of Kaletra-based therapy in treatment-naïve HIV patients
1 December 2003. Related: Conference reports, Antiretrovirals.
IL-2 effectively increases CD4 count in people with low CD4 nadir
1 December 2003. Related: Conference reports, Basic science and immunology.
Hepatitis coinfection: incidence in Europe and response to transplant
1 December 2003. Related: Conference reports, Hepatitis coinfection.
Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)
1 December 2003. Related: Conference reports, Antiretrovirals, Cancer and HIV.
Access to treatment – some progress…
1 December 2003. Related: Treatment access.
WHO approves combination pills
1 December 2003. Related: Treatment access.
South African Competition Commission finds GSK and BI responsible for ‘excessive pricing’ and ‘abuse of market position’
1 December 2003. Related: Treatment access.
FTC (emtricitabine, Emtriva) approved in Europe
1 December 2003. Related: Antiretrovirals.
EMEA recommend approval for atazanavir for treatment experienced patients
1 December 2003. Related: Antiretrovirals.
Fosamprenavir (Lexiva) approved in US
1 December 2003. Related: Antiretrovirals.
Polylactic acid (New-gill) repairs facial wasting and improves quality of life
1 December 2003. Related: Lipodystrophy and metabolic complications.
US paediatric, adult and maternal-child guidelines updated
1 December 2003. Related: Antiretrovirals.
Increased risk of myocardial infarction associated with duration of protease inhibitor treatment
1 December 2003. Related: Side effects.
UK guidelines for treating coinfection with HIV and hepatitis B or C published online
1 December 2003. Related: Hepatitis coinfection.
Kidney and liver transplantation in HIV-infected patients: case presentations and review
1 December 2003. Related: Hepatitis coinfection.
London epidemic of sexually transmitted hepatitis C
1 December 2003. Related: Hepatitis coinfection.
Dramatic decline in mortality, disease progression and hospital admissions in children with HIV infection in the UK and Ireland
1 December 2003. Related: Paediatric care.
New tool for assessing risks of disease progression and death based on age, CD4 percentage and viral load in HIV-infected children
1 December 2003. Related: Paediatric care.
VaxGen AIDSVAX vaccine fails in Thailand
1 December 2003. Related: Vaccines and microbicides.
Access to HIV treatment in Eastern Europe
1 December 2003. Related: Treatment access.
Conferences
1 December 2003. Related: On the web.
Online medical lectures
1 December 2003. Related: On the web.
Newsletters and reports
1 December 2003. Related: On the web.
HIV and hepatitis coinfection
1 December 2003. Related: On the web.
Other news
1 December 2003. Related: On the web.
Volume 4 Number 9 November 2003
1 November 2003. Related: Editorial.
Important safety information: high rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI combination containing ddI, 3TC, and tenofovir DF
1 November 2003. Related: Treatment alerts.
13th International Conference on AIDS and STIs in Africa (ICASA), 21-26 September 2003, Nairobi
1 November 2003. Related: Conference reports.
STIs in resource limited settings
1 November 2003. Related: Conference reports, Treatment strategies.
43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago
1 November 2003. Related: Conference reports.
ddI may retain activity in nucleoside experienced patients
1 November 2003. Related: Conference reports, Antiretrovirals.
Studies and strategies with existing drugs
1 November 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Incremental progress with new antiviral drugs
1 November 2003. Related: Conference reports, Antiretrovirals.
Newer nucleoside analogues show fewer adverse effects
1 November 2003. Related: Conference reports, Side effects.
Interaction between amprenavir and lopinavir thwarts triple PI salvage
1 November 2003. Related: PK and drug interactions.
Vitamin C induces P4503A4 and reduces indinavir levels
1 November 2003. Related: PK and drug interactions.
Indinavir levels reduced by omeprazole
1 November 2003. Related: PK and drug interactions.
Boosted saquinavir PK in once-daily regimes
1 November 2003. Related: PK and drug interactions.
Tenofovir drug-drug interactions
1 November 2003. Related: PK and drug interactions.
Summary of other PK studies
1 November 2003. Related: PK and drug interactions.
Global AIDS spending must double by 2005, says gloomy UN
1 November 2003. Related: Treatment access.
GARPP requests permission from Boehringer to import generic nevirapine
1 November 2003. Related: Treatment access.
Canada decides to lead the way in exempting AIDS drugs from patent laws
1 November 2003. Related: Treatment access.
Atazanavir ‘named-patient’ access extended in the UK and includes 150mg capsule
1 November 2003. Related: Antiretrovirals.
Another triple nuke failure: abacavir/ddI/d4T
1 November 2003. Related: Antiretrovirals.
FDA announces changes to ritonavir package insert
1 November 2003. Related: Antiretrovirals.
Treatment interruption prior to five-drug regime shows no benefit at 48 weeks
1 November 2003. Related: Treatment strategies.
Failure of alternating week-on and week-off therapy
1 November 2003. Related: Treatment strategies.
Canadian study shows increased interventional cardiovascular procedures associated with HAART
1 November 2003. Related: Lipodystrophy and metabolic complications.
Valacyclovir is effective prophylaxis against herpes simplex
1 November 2003. Related: Coinfections and complications.
Antiviral dynamics and sex differences of AZT and 3TC triphosphate concentrations
1 November 2003. Related: Women's health.
Women have a greater immunological response to effective HAART
1 November 2003. Related: Women's health.
Use of rapid HIV tests in labour
1 November 2003. Related: Pregnancy.
Eighteen-month findings of HIVNET 012
1 November 2003. Related: Pregnancy.
Rituximab as single agent reversed paediatric Non-Hodgkins Lymphoma (NHL)
1 November 2003. Related: Paediatric care.
Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants
1 November 2003. Related: Paediatric care.